Clinical consequences of hyperglycemia during remission induction therapy for pediatric acute lymphoblastic leukemia
- PMID: 18923438
- PMCID: PMC2706830
- DOI: 10.1038/leu.2008.289
Clinical consequences of hyperglycemia during remission induction therapy for pediatric acute lymphoblastic leukemia
Abstract
Hyperglycemia adversely affects outcome in adult patients with acute lymphoblastic leukemia (ALL), but its impact on children with this disease is unknown. We evaluated the relationship between hyperglycemia during remission induction therapy and clinical outcomes among pediatric patients with ALL. We reviewed the records of patients enrolled on four consecutive ALL protocols (Total Therapy protocols XIIIA, XIIIB, XIV and XV) at St Jude Children's Research Hospital from 1991 to 2007 and identified those who experienced hyperglycemia (glucose >or=200 mg per 100 ml) during remission induction. Complete remission (CR) rates at the end of induction, event-free survival (EFS), overall survival (OS), cumulative incidence of relapse and occurrence of infections were compared between those who did and did not experience hyperglycemia. Of 871 patients analyzed, 141 (16%) experienced hyperglycemia during remission induction. Patients with hyperglycemia were significantly older than the other patients (P<0.0001). There was no significant difference in CR rate (P=0.92), EFS (P=0.80), OS (P=0.28), cumulative incidence of relapse (P=0.59) or in the probability or types of infection between patients who did and did not experience hyperglycemia. Pediatric patients with or without hyperglycemia during remission induction for ALL have similar clinical outcome. Occurrence of hyperglycemia does not warrant alteration of the antileukemic regimen.
Similar articles
-
The long-term results of childhood acute lymphoblastic leukemia at two centers from Turkey: 15 years of experience with the ALL-BFM 95 protocol.Ann Hematol. 2014 Oct;93(10):1677-84. doi: 10.1007/s00277-014-2106-0. Epub 2014 May 27. Ann Hematol. 2014. PMID: 24863691
-
Treating childhood acute lymphoblastic leukemia in a developing country 1998-2003: the experience of a single children's hospital in China.J Pediatr Hematol Oncol. 2006 Dec;28(12):798-802. doi: 10.1097/MPH.0b013e31802d3e7a. J Pediatr Hematol Oncol. 2006. PMID: 17164648
-
Benefit of high-dose methylprednisolone in comparison with conventional-dose prednisolone during remission induction therapy in childhood acute lymphoblastic leukemia for long-term follow-up.Leukemia. 2003 Feb;17(2):328-33. doi: 10.1038/sj.leu.2402673. Leukemia. 2003. PMID: 12592331 Clinical Trial.
-
Hematopoietic stem cell transplantation following unsuccessful salvage treatment for relapsed acute lymphoblastic leukemia in children.Pediatr Blood Cancer. 2015 Apr;62(4):674-9. doi: 10.1002/pbc.25353. Epub 2014 Dec 24. Pediatr Blood Cancer. 2015. PMID: 25546601
-
Non-relapse mortality in pediatric acute lymphoblastic leukemia: a systematic review and meta-analysis.Leuk Lymphoma. 2012 May;53(5):878-85. doi: 10.3109/10428194.2011.639018. Epub 2012 Jan 3. Leuk Lymphoma. 2012. PMID: 22066711 Review.
Cited by
-
Hyperglycemia during induction therapy for acute lymphoblastic leukemia is temporally linked to pegaspargase administration.Pediatr Blood Cancer. 2022 Jul;69(7):e29505. doi: 10.1002/pbc.29505. Epub 2021 Dec 21. Pediatr Blood Cancer. 2022. PMID: 34931744 Free PMC article.
-
Hyperglycemia requiring insulin during acute lymphoblastic leukemia induction chemotherapy is associated with increased adverse outcomes and healthcare costs.Pediatr Blood Cancer. 2020 Sep;67(9):e28475. doi: 10.1002/pbc.28475. Epub 2020 Jun 26. Pediatr Blood Cancer. 2020. PMID: 32589365 Free PMC article.
-
Stress-induced hyperglycemia is a valuable biomarker in febrile neutropenia.Rev Bras Hematol Hemoter. 2013;35(1):12-4. doi: 10.5581/1516-8484.20130006. Rev Bras Hematol Hemoter. 2013. PMID: 23580876 Free PMC article. No abstract available.
-
Evaluation of changes in random blood glucose and body mass index during and after completion of chemotherapy in children with acute lymphoblastic leukemia.Korean J Pediatr. 2012 Apr;55(4):121-7. doi: 10.3345/kjp.2012.55.4.121. Epub 2012 Apr 30. Korean J Pediatr. 2012. PMID: 22574072 Free PMC article.
-
Diabetes mellitus among adult survivors of childhood acute lymphoblastic leukemia: A report from the St. Jude Lifetime Cohort Study.Cancer. 2020 Feb 15;126(4):870-878. doi: 10.1002/cncr.32596. Epub 2019 Nov 12. Cancer. 2020. PMID: 31714590 Free PMC article.
References
-
- Iyer RS, Rao SR, Pai S, Advani SH, Magrath IT. L-asparaginase related hyperglycemia. Indian J Cancer. 1993 Jun;30(2):72–6. - PubMed
-
- Jaffe N, Traggis D, Das L, Frauenberger G, Hann HW, Kim BS, et al. Favorable remission induction rate with twice weekly doses of L-asparaginase. Cancer Res. 1973 Jan;33(1):1–4. - PubMed
-
- Jaffe N, Traggis D, Das L, Kim BS, Won H, Hann L, et al. Comparison of daily and twice-weekly schedule of L-asparaginase in childhood leukemia. Pediatrics. 1972 Apr;49(4):590–5. - PubMed
-
- Lavine RL, DiCinto DM. L-Asparaginase diabetes mellitus in rabbits: differing effects of two different schedules of L-asparaginase administration. Horm Metab Res. 1984 Dec;16(Suppl 1):92–6. - PubMed
-
- Lavine RL, Brodsky I, Garofano CD, Rose LI. The effect of E. coli L-asparaginase on oral glucose tolerance and insulin release in man. Diabetologia. 1978 Aug;15(2):113–6. - PubMed
Publication types
MeSH terms
Grants and funding
- U01 GM061393-09/GM/NIGMS NIH HHS/United States
- CA-78224/CA/NCI NIH HHS/United States
- R01 CA060419-13/CA/NCI NIH HHS/United States
- U01 GM061393/GM/NIGMS NIH HHS/United States
- CA-60419/CA/NCI NIH HHS/United States
- R01 CA051001-15/CA/NCI NIH HHS/United States
- R01 CA078224/CA/NCI NIH HHS/United States
- R37 CA036401/CA/NCI NIH HHS/United States
- P30 CA021765-30/CA/NCI NIH HHS/United States
- CA-36401/CA/NCI NIH HHS/United States
- R01 CA060419/CA/NCI NIH HHS/United States
- CA-51001/CA/NCI NIH HHS/United States
- CA-21765/CA/NCI NIH HHS/United States
- P30 CA021765/CA/NCI NIH HHS/United States
- R37 CA036401-21/CA/NCI NIH HHS/United States
- R01 CA078224-09/CA/NCI NIH HHS/United States
- R01 CA051001/CA/NCI NIH HHS/United States
- R01 CA036401/CA/NCI NIH HHS/United States
- GM-61393/GM/NIGMS NIH HHS/United States
- U01 CA060419/CA/NCI NIH HHS/United States
LinkOut - more resources
Full Text Sources
Medical